Sun Pharma voluntarily recalls 11 eye-drop products from India market
Sun Pharmaceutical Industries has withdrawn 11 ophthalmic products from the domestic market as a precautionary quality and patient-safety measure. The company has not disclosed the affected batches, manufacturing sites, cause of the recall or remediation timeline.
Sun Pharma voluntarily withdrew some ophthalmic products from India’s domestic market, with reports indicating 11 eyedrops. The company cited precautionary quality and patient-safety measures but did not disclose causes, batches, manufacturing locations or remediation details.
Why this matters
The withdrawal follows a recent Sun Pharma signal on select eye-drop recalls and halted distributor sales. It comes after the company missed Q1 estimates on weaker US generics sales, despite 16% growth in India formulations sales.
Retail-company signals are accelerating, up 227400% QoQ.